Advertisement
Australia markets close in 5 hours 55 minutes

  • ALL ORDS

    7,952.30
    +54.80 (+0.69%)
     

  • ASX 200

    7,682.40
    +53.40 (+0.70%)
     

  • AUD/USD

    0.6629
    +0.0004 (+0.06%)
     

  • OIL

    78.91
    +0.43 (+0.55%)
     

  • GOLD

    2,334.90
    +3.70 (+0.16%)
     

  • Bitcoin AUD

    95,286.30
    -1,474.67 (-1.52%)
     

  • CMC Crypto 200

    1,360.26
    +47.63 (+3.63%)
     

  • AUD/EUR

    0.6154
    +0.0008 (+0.13%)
     

  • AUD/NZD

    1.1022
    +0.0002 (+0.02%)
     

  • NZX 50

    11,809.35
    -11.43 (-0.10%)
     

  • NASDAQ

    18,093.57
    +202.77 (+1.13%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,852.27
    +176.59 (+0.46%)
     

  • DAX

    18,175.21
    +173.61 (+0.96%)
     

  • Hang Seng

    18,578.30
    +102.38 (+0.55%)
     

  • NIKKEI 225

    38,236.07
    0.00 (0.00%)
     

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Sensei Biotherapeutics
·2-min read
Sensei Biotherapeutics
Sensei Biotherapeutics

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.

The panel will feature Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas. Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101.

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

ADVERTISEMENT

Investor Contact: 
Michael Biega 
Senior Director, Investor Relations
Sensei Biotherapeutics 
mbiega@senseibio.com

Media Contact: 
Joyce Allaire 
LifeSci Advisors 
Jallaire@lifesciadvisors.com